Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. StageZero Life Sciences's accounts receivables for the quarter that ended in Sep. 2024 was $0.09 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
StageZero Life Sciences's Days Sales Outstanding for the quarter that ended in Sep. 2024 was 16.97.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. StageZero Life Sciences's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $-0.09.
StageZero Life Sciences Accounts Receivable Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
StageZero Life Sciences's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), StageZero Life Sciences's accounts receivable are only considered to be worth 75% of book value:
StageZero Life Sciences's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
StageZero Life Sciences Accounts Receivable Related Terms
StageZero Life Sciences Accounts Receivable Historical Data
* Premium members only.
The historical data trend for StageZero Life Sciences's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of $0.09 Mil mean?
StageZero Life Sciences (SZLSF) has a Accounts Receivable of $0.09 Mil as of Sep. 2024. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' Accounts Receivable too high?
StageZero Life Sciences' current Accounts Receivable is $0.09 Mil. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Accounts Receivable compare to IDTA and TTOO?
StageZero Life Sciences' Accounts Receivable of $0.09 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Diagnostics & Research company?
A good Accounts Receivable depends on the Medical Diagnostics & Research industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on StageZero Life Sciences and its competitors. StageZero Life Sciences's current Accounts Receivable is $0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (SZLSF) has a current Accounts Receivable of $0.09 Mil. The current Accounts Receivable is $0.09 Mil. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For StageZero Life Sciences (SZLSF), the current Accounts Receivable is $0.09 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score
Get the complete analysis for SZLSF
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZLSF has been successfully added to your 
